Wednesday, February 10, 2010, 2:41PM AEST - The Australian Stockmarket closes in 1 hour and 24 minutes.
To create a watchlist or portfolio of shares, Register

Impax Laboratories Inc. (IPXL)

 8:00AM AEST: 13.66 USD  Up 0.02 (0.15%)  
 MORE ON IPXL 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Impax Laboratories, Inc. (NGM:IPXL) Delayed quote dataEdit
Last Trade:13.66 USD
Trade Time: 8:00AM AEST
Change:Up 0.02 (0.15%)
Prev Close:13.64
Open:13.75
Bid:12.88 x 100
Ask:N/A
1y Target Est:16.00
Day's Range:13.50 - 13.93
52wk Range:3.00 - 14.87
Volume:358,109
Avg Vol (3m):586,606
Market Cap:845.20M
P/E (ttm):35.12
EPS (ttm):0.39
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y 
 Add IPXL to Portfolio   Download Data

 HEADLINES 
•2010 Health Care Stock Winners With Or Without Congressional Legislation
Wall Street Transcript (Thu, Jan 28)
•Molecular Diagnostics And Point Of Care Diagnostics Companies Lead Buy List From Bleichroeder For 2010
Wall Street Transcript (Tue, Jan 26)
•Impax Laboratories Earnings Call scheduled for Thu, Feb 25
CCBN (Fri, Jan 22)
•Impax Laboratories Schedules Conference Call for Fourth Quarter and Full Year 2009 Financial Results
Business Wire (Fri, Jan 22)
•Impax challenges Genzyme, partner on Welchol
AP (Sat, Jan 16)
•UPDATE - Daiichi Sankyo's cholesterol drug gets generic threat
at Reuters (Sat, Jan 16)
•Impax Laboratories Confirms Patent Challenge Relating to WELCHOL® 625 mg Tablets
Business Wire (Sat, Jan 16)
•IMPAX LABORATORIES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibi
EDGAR Online (Fri, Jan 15)
•IMPAX LABORATORIES INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
EDGAR Online (Wed, Jan 13)
•Top Sectors for 2010: 1 Minute Trade
TheStreet.com TV (Tue, Jan 12)
More Headlines for IPXL...
 ANALYST 
EPS Est (next year) (Dec-09) :0.34
EPS Est (in 2 years) (Dec-10) :0.92
Avg Rec (current)*:2.1
PEG Ratio:1.15
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Impax Laboratories, Inc. engages in the development and commercialization of bioequivalent and brand-name pharmaceuticals. It operates through two divisions, Global Pharmaceuticals and Impax Pharmaceutical.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
•Latest News•7 Indices